African Health Economics and Policy Association

Ariadne Labs Announces 2022-2023 Spark Grant Recipients

Retrieved on: 
Wednesday, January 11, 2023
MPH, Community, Tufts University School of Medicine, Trust, Anesthesiology, Conservation Innovation Grants, Community health worker, Cone Health Women's Hospital, University, Stroke, Language, Motivation, Reproductive biology, Death, Assistant professor, Health, EVT, Mortality, Research, Harvard Medical School, Ariadne, Doctor of Philosophy, Colorado Department of Health Care Policy and Financing, Checklist, Disease, Morbidity and mortality conference, Pivot, Social medicine, MMCS, African Health Economics and Policy Association, MPP, Triage, Communication, Safety, Hospital, Beth Israel Deaconess Medical Center, Assistant, Patient, New England Hospital for Women and Children, HMS, Science, Faculty, Pharmaceutical industry, Medicine, Management, Gynaecology, MD, Obstetrics, Policy

BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year. The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients. Now in its tenth year, the program has funded more than 20 projects. 

Key Points: 
  • Five grants will support early-stage ideas to make health care safer, more integrated, and more equitable
    BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year.
  • The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients.
  • The 2022-2023 recipients of the Ariadne Labs Spark Grant innovation awards are:
    Rose Molina, MD, MPH, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School; Obstetrician-Gynecologist at Beth Israel Deaconess Medical Center and The Dimock Center; Core Faculty at Ariadne Labs
    Evidence suggests that individuals with limited English language proficiency experience lower quality maternal health care due to structural barriers and communication challenges.
  • In 2021 a Spark Grant funded initial work to develop a checklist to triage potential candidates for EVT.

Amy Schumer Joins the Board of Directors of the Hyperemesis Education and Research (HER) Foundation

Retrieved on: 
Thursday, May 12, 2022
MOM, Risk, Education, USC, Nausea, Loss, HER, Mother, Foundation, HG, Hyperemesis gravidarum, HER Foundation, African Health Economics and Policy Association, End organ damage, Awareness, Golden Globe Awards, BJOG, GDF15, Schumer, Board, Pregnancy, Debility, Anxiety, Human, Board of directors, Vomiting, Functional gastrointestinal disorder, Dehydration, Preterm birth, Malnutrition, Coagulopathy, Autism, Pre-eclampsia, Diagnosis, Weight loss, ADD/ADHD, Birth control, Research

Schumer experienced Hyperemesis Gravidarum while pregnant with her son, Gene, and documented the journey with husband, Chris Fischer, in her docuseries, Expecting Amy.

Key Points: 
  • Schumer experienced Hyperemesis Gravidarum while pregnant with her son, Gene, and documented the journey with husband, Chris Fischer, in her docuseries, Expecting Amy.
  • Executive Director and co-founder, Kimber MacGibbon, a Registered Nurse who appears in Expecting Amy , is pleased to welcome Schumer to the Board.
  • Schumer will join other sector leaders on the HER Foundation's Board of Directors to guide operations and programs which include crisis support services, patient and provider education, breakthrough research, awareness, and advocacy.
  • The Hyperemesis Education and Research (HER) Foundation is a 501(c)3 nonprofit that provides support, groundbreaking research, advocacy, and education on hyperemesis gravidarum (HG), a debilitating disease of pregnancy.

Ambys Medicines Appoints Dr. Corinne Foo-Atkins as Chief Strategy Officer

Retrieved on: 
Thursday, January 20, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Fatty liver disease, Patient, London School of Hygiene & Tropical Medicine, MBBS, Kellogg School, Policy, LinkedIn, Liver, National University of Singapore, African Health Economics and Policy Association, Genentech, McKinsey & Company, MBA, Growth, Novartis, Institute of Liver and Biliary Sciences, Death, National university, London, Leadership, Instagram, Health policy, Master of Science, Strategic planning, Company, Drug development, CGMP, Retina, Hematology, Business, Twitter, Liver disease, Liver failure, Corinne, Management, Medical imaging, Economics, MD, Ambi Subramaniam

Ambys Medicines , a company pioneering cell-based therapies for severe liver diseases, today announced the appointment of Corinne Foo-Atkins, MBBS, MBA, MSc, as the companys first Chief Strategy Officer.

Key Points: 
  • Ambys Medicines , a company pioneering cell-based therapies for severe liver diseases, today announced the appointment of Corinne Foo-Atkins, MBBS, MBA, MSc, as the companys first Chief Strategy Officer.
  • She will report to Ambyss CEO, Ronald Park, MD, and will serve as a member of the companys executive committee.
  • Dr. Foo-Atkins brings over 25 years of life sciences and medical experience to Ambys.
  • Ambys Medicines is focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease.